Neuroptix Corp., an Acton company working on a test for the detection of Alzheimer’s disease, has received $4 million in venture funding.
The $4 million is the first tranche of a Series C funding round. The investment, led by Inventages, will be funded in two tranches totaling $8 million, according to Neuroptix.
The Neuroptix SAPPHIRE II System is a non-invasive eye test for Alzheimer’s. It works by looking for proteins that form in both the brain and the lens of the eye in people with the disease.
